心血管

订阅

MedSci主页 / 所有栏目 / 心血管

JACC：evolocumab与脂蛋白(a)的相关性

2014-02-11 晓静 译 医学论坛网

降脂治疗新药Evolocumab脂蛋白aLDL—C
关注

一项多国联合研究表明，PCSK9单克隆抗体evolocumab (AMG 145)与脂蛋白(a)[Lp(a)]水平降低存在显著的剂量相关性。对那些基线Lp(a)≤125 nmol/L患者的Lp(a)平均水平降低百分比较为显著，对基线Lp(a)>125 nmol/L的患者绝对降低幅度更大。相关论文2月5日在线发表于《美国心脏病学会杂志》(简称JACC)。 在流行病学研究中，Lp(a)

一项多国联合研究表明，PCSK9单克隆抗体evolocumab (AMG 145)与脂蛋白(a)[Lp(a)]水平降低存在显著的剂量相关性。对那些基线Lp(a)≤125 nmol/L患者的Lp(a)平均水平降低百分比较为显著，对基线Lp(a)>125 nmol/L的患者绝对降低幅度更大。相关论文2月5日在线发表于《美国心脏病学会杂志》(简称JACC)。

在流行病学研究中，Lp(a)、低密度脂蛋白(LDL)颗粒与心血管疾病风险呈独立正相关性。当前鲜有治疗手段去减少Lp(a)。该研究的研究者对4期2项试验中的1359例患者进行了汇集分析，评估evolocumab对Lp(a)的效果，以及Lp(a)与低密度脂蛋白胆固醇(LDL—C)和载脂蛋白B降低的关系，他汀类药物治疗的影响。评估患者的Lp(a)水平。

结果显示，与对照组相比，应用evolocumab治疗12周可使受试者的Lp(a)平均剂量相关降低显著(P<0.001);每2周和每4周应用140 mg和420 mg分别降低29.5 (23.3 ~35.7)% 和 24.5 (20.4 ~28.7)%，无平台期。Lp(a)减少与LDL-C和载脂蛋白B减少的百分比显著相关(P值均<0. 001)。基于年龄和性别的平均降低百分比无差异，但在接受他汀类药物治疗的受试者中其幅度趋向更大。

原始出处：

Frederick J. Raal, MB BCh, MMED, PhD; Robert P. Giugliano, MD, SM; Marc S. Sabatine, MD, MPH; Michael J. Koren, MD‡; Gisle Langslet, MD§; Harold Bays, M; Dirk Blom, PhD, MD; Mats Eriksson, MD; Ricardo Dent, MD; Scott M. Wasserman, MD; Fannie Huang, MS; Allen Xue, PhD; Moetaz Albizem, MD; Rob Scott, MD; Evan A. Stein, MD, PhD††.Reduction in lipoprotein (a) with the PCSK9 monoclonal antibody evolocumab (AMG 145): a pooled analysis of over 1300 patients in 4 phase 2 trials ONLINE FIRST.J Am Coll Cardiol. 2014;():. doi:10.1016/j.jacc.2014.01.006

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1837133, encodeId=35ce183e13355, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Sat Aug 30 17:38:00 CST 2014, time=2014-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1911636, encodeId=79961911636c6, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Wed May 21 22:38:00 CST 2014, time=2014-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1853269, encodeId=b02b185326954, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Wed Dec 31 12:38:00 CST 2014, time=2014-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1324879, encodeId=382513248e9d0, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Thu Feb 13 02:38:00 CST 2014, time=2014-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1424636, encodeId=b2d514246361c, content=<a href='/topic/show?id=5a3b8441438' target=_blank style='color:#2F92EE;'>#脂蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84414, encryptionId=5a3b8441438, topicName=脂蛋白)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=23ea3924919, createdName=juliusluan79, createdTime=Thu Feb 13 02:38:00 CST 2014, time=2014-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1426465, encodeId=184f142646568, content=<a href='/topic/show?id=96fae1243b' target=_blank style='color:#2F92EE;'>#Evolocumab#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7124, encryptionId=96fae1243b, topicName=Evolocumab)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ce534073393, createdName=ZGMFX25A, createdTime=Thu Feb 13 02:38:00 CST 2014, time=2014-02-13, status=1, ipAttribution=)]
    2014-08-30 shenxlcyp

    #相关性#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1837133, encodeId=35ce183e13355, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Sat Aug 30 17:38:00 CST 2014, time=2014-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1911636, encodeId=79961911636c6, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Wed May 21 22:38:00 CST 2014, time=2014-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1853269, encodeId=b02b185326954, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Wed Dec 31 12:38:00 CST 2014, time=2014-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1324879, encodeId=382513248e9d0, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Thu Feb 13 02:38:00 CST 2014, time=2014-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1424636, encodeId=b2d514246361c, content=<a href='/topic/show?id=5a3b8441438' target=_blank style='color:#2F92EE;'>#脂蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84414, encryptionId=5a3b8441438, topicName=脂蛋白)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=23ea3924919, createdName=juliusluan79, createdTime=Thu Feb 13 02:38:00 CST 2014, time=2014-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1426465, encodeId=184f142646568, content=<a href='/topic/show?id=96fae1243b' target=_blank style='color:#2F92EE;'>#Evolocumab#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7124, encryptionId=96fae1243b, topicName=Evolocumab)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ce534073393, createdName=ZGMFX25A, createdTime=Thu Feb 13 02:38:00 CST 2014, time=2014-02-13, status=1, ipAttribution=)]
    2014-05-21 snf701207

    #mAb#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1837133, encodeId=35ce183e13355, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Sat Aug 30 17:38:00 CST 2014, time=2014-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1911636, encodeId=79961911636c6, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Wed May 21 22:38:00 CST 2014, time=2014-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1853269, encodeId=b02b185326954, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Wed Dec 31 12:38:00 CST 2014, time=2014-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1324879, encodeId=382513248e9d0, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Thu Feb 13 02:38:00 CST 2014, time=2014-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1424636, encodeId=b2d514246361c, content=<a href='/topic/show?id=5a3b8441438' target=_blank style='color:#2F92EE;'>#脂蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84414, encryptionId=5a3b8441438, topicName=脂蛋白)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=23ea3924919, createdName=juliusluan79, createdTime=Thu Feb 13 02:38:00 CST 2014, time=2014-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1426465, encodeId=184f142646568, content=<a href='/topic/show?id=96fae1243b' target=_blank style='color:#2F92EE;'>#Evolocumab#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7124, encryptionId=96fae1243b, topicName=Evolocumab)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ce534073393, createdName=ZGMFX25A, createdTime=Thu Feb 13 02:38:00 CST 2014, time=2014-02-13, status=1, ipAttribution=)]
    2014-12-31 hbwxf

    #JACC#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1837133, encodeId=35ce183e13355, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Sat Aug 30 17:38:00 CST 2014, time=2014-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1911636, encodeId=79961911636c6, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Wed May 21 22:38:00 CST 2014, time=2014-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1853269, encodeId=b02b185326954, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Wed Dec 31 12:38:00 CST 2014, time=2014-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1324879, encodeId=382513248e9d0, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Thu Feb 13 02:38:00 CST 2014, time=2014-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1424636, encodeId=b2d514246361c, content=<a href='/topic/show?id=5a3b8441438' target=_blank style='color:#2F92EE;'>#脂蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84414, encryptionId=5a3b8441438, topicName=脂蛋白)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=23ea3924919, createdName=juliusluan79, createdTime=Thu Feb 13 02:38:00 CST 2014, time=2014-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1426465, encodeId=184f142646568, content=<a href='/topic/show?id=96fae1243b' target=_blank style='color:#2F92EE;'>#Evolocumab#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7124, encryptionId=96fae1243b, topicName=Evolocumab)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ce534073393, createdName=ZGMFX25A, createdTime=Thu Feb 13 02:38:00 CST 2014, time=2014-02-13, status=1, ipAttribution=)]
    2014-02-13 12498568m50暂无昵称

    #ACC#

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1837133, encodeId=35ce183e13355, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Sat Aug 30 17:38:00 CST 2014, time=2014-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1911636, encodeId=79961911636c6, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Wed May 21 22:38:00 CST 2014, time=2014-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1853269, encodeId=b02b185326954, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Wed Dec 31 12:38:00 CST 2014, time=2014-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1324879, encodeId=382513248e9d0, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Thu Feb 13 02:38:00 CST 2014, time=2014-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1424636, encodeId=b2d514246361c, content=<a href='/topic/show?id=5a3b8441438' target=_blank style='color:#2F92EE;'>#脂蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84414, encryptionId=5a3b8441438, topicName=脂蛋白)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=23ea3924919, createdName=juliusluan79, createdTime=Thu Feb 13 02:38:00 CST 2014, time=2014-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1426465, encodeId=184f142646568, content=<a href='/topic/show?id=96fae1243b' target=_blank style='color:#2F92EE;'>#Evolocumab#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7124, encryptionId=96fae1243b, topicName=Evolocumab)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ce534073393, createdName=ZGMFX25A, createdTime=Thu Feb 13 02:38:00 CST 2014, time=2014-02-13, status=1, ipAttribution=)]
    2014-02-13 juliusluan79

    #脂蛋白#

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1837133, encodeId=35ce183e13355, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Sat Aug 30 17:38:00 CST 2014, time=2014-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1911636, encodeId=79961911636c6, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Wed May 21 22:38:00 CST 2014, time=2014-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1853269, encodeId=b02b185326954, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Wed Dec 31 12:38:00 CST 2014, time=2014-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1324879, encodeId=382513248e9d0, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Thu Feb 13 02:38:00 CST 2014, time=2014-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1424636, encodeId=b2d514246361c, content=<a href='/topic/show?id=5a3b8441438' target=_blank style='color:#2F92EE;'>#脂蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84414, encryptionId=5a3b8441438, topicName=脂蛋白)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=23ea3924919, createdName=juliusluan79, createdTime=Thu Feb 13 02:38:00 CST 2014, time=2014-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1426465, encodeId=184f142646568, content=<a href='/topic/show?id=96fae1243b' target=_blank style='color:#2F92EE;'>#Evolocumab#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7124, encryptionId=96fae1243b, topicName=Evolocumab)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ce534073393, createdName=ZGMFX25A, createdTime=Thu Feb 13 02:38:00 CST 2014, time=2014-02-13, status=1, ipAttribution=)]
    2014-02-13 ZGMFX25A

    #Evolocumab#

    0